| Literature DB >> 29523201 |
Sara Andrés-Lasheras1, Inma Martín-Burriel2, Raúl Carlos Mainar-Jaime1, Mariano Morales1,3, Ed Kuijper4, José L Blanco5, Manuel Chirino-Trejo6, Rosa Bolea7.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is recognised as an emerging disease in both humans and some animal species. During the past few years, insights into human CDI epidemiology changed and C. difficile is also considered as an emerging community-acquired pathogen. Certain ribotypes (RT) are possibly associated with zoonotic transmission. The objective of this study was to assess the presence of C. difficile in a population of pets and to characterise the isolates.Entities:
Keywords: Clostridium difficile; Dog; Exotic; MLST; Metronidazole-resistant; PCR-ribotyping
Mesh:
Year: 2018 PMID: 29523201 PMCID: PMC5845233 DOI: 10.1186/s12917-018-1402-7
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Characteristics of the dog population included in the study
| Variable | Number samples (%) | Number positive samples (%) to CD |
| Number toxigenic CD strains (%)b |
|---|---|---|---|---|
| Gender | 1 | |||
| Female | 47 (52.2) | 3 (6.4) | 2 (4.2) | |
| Male | 43 (47.8) | 3 (7) | 2 (4.6) | |
| Agec | 0.42 | |||
| 0–4 m | 25 (27.8) | 2 (8) | 2 (8) | |
| 5–12 m | 21 (23.3) | 0 | 0 | |
| 13–72 m | 21 (23.3) | 2 (9.5) | 2 (9.5) | |
| ≥ 73 m | 9 (10) | 0 | 0 | |
| Spanish geographical region | 0.77 | |||
| North | 36 (40) | 2 (5.6) | 2 (5.6) | |
| Northeast | 42 (46.7) | 3 (7.1) | 2 (4.8) | |
| Centre | 7 (7.8) | 1 (14.3) | 0 | |
| Southeast | 5 (5.5) | 0 | 0 | |
| Season | 0.71 | |||
| Winter | 31 (34.4) | 1 (3.2) | 1 (3.2) | |
| Spring | 9 (10) | 1 (11.1) | 1 (11.1) | |
| Summer | 3 (3.3) | 0 | 0 | |
| Fall | 47 (52.2) | 4 (8.5) | 2 (4.3) | |
| Breedd | 0.63 | |||
| Large | 40 (44.4) | 2 (5) | 1 (2.5) | |
| Medium | 29 (32.2) | 2 (6.9) | 2 (6.9) | |
| Small | 13 (14.4) | 0 | 0 | |
| Dysbiosis | 0.66 | |||
| No | 28 (31.1) | 1 (3.6) | 0 | |
| Yes | 62 (68.9) | 5 (8.1) | 4 (6.5) | |
CD Clostridium difficile; aUnivariable logistic regression; bpercentages calculated from the total number of samples; cage unknown for 14 samples (two of them are positive to non-toxigenic C. difficile); dbreed unknown for eight samples (one of them is positive to toxigenic C. difficile and another one to non-toxigenic C. difficile)
Molecular characterization of Clostridium difficile isolates
| IDa | Toxin genes | NTSb | Toxinotype | RT | ST | MIC0/MICS to MZc |
|---|---|---|---|---|---|---|
| D18 | NA | 0 | 014 | – | – | |
| D21 | – | + | NA | 123 | – | – |
| D24d | NA | 0 | 014 | – | 128/96 | |
| D57 | NA | 0 | 358 | – | – | |
| D66 | NA | 0 | 014 | – | – | |
| D83d | – | + | NA | 010 | – | 48/32 |
| E6 | – | – | NA | New | 347 | – |
RT PCR-ribotype, ST sequence type, MIC0: initial minimal inhibitory concentration to metronidazole (μg/ml), MIC: minimal inhibitory concentration to metronidazole after repeated passages (μg/ml), MZ metronidazole, NA not applicable, D dog’s strain, E exotic species strain; aisolate identification; bnon-toxigenic strains PCR; cinitial metronidazole-resistant isolates stability experiment results; dmetronidazole and multidrug-resistant isolates
Fig. 1Molecular phylogenetic analysis (maximum likelihood method) from concatenated MLST alleles. Clostridium difficile isolates corresponding to our collection are showed with a circle. ST, sequence type; Hu, human isolate; RC, rat intestinal content isolate; 5754, sow vagina isolate; RF, environmental rat faeces isolate; E, exotic animal isolate
In vitro activity of six antimicrobials against the Clostridium difficile dog isolates
| Antimicrobial agent | Range (μg/ml) | Breakpointa (μg/ml) | Number resistant isolates (%) |
|---|---|---|---|
| Clindamycin | 0′016–256 | ≥8b | 3/6 (50) |
| Erythromycin | 0′016–256 | ≥8 | 2/6 (33.3) |
| Metronidazole | 0′016–256 | ≥32b | 2/6 (33.3) |
| Moxifloxacin | 0′02–32 | ≥8b | 1/6 (16.7) |
| Tetracycline | 0′016–256 | ≥8 | 0 |
| Vancomycin | 0′016–256 | ≥32 | 0 |
aThe breakpoints for resistance established by the Clinical and Laboratory Standards Institute (CLSI) for anaerobic bacteria are those marked by b [50]. The breakpoint for tetracycline was ≥8 μg/ml [51]. The remaining breakpoints were based on the literature [7]
Fig. 2Metronidazole susceptibility test of Clostridium difficile D24 strain after 48 h of incubation. GI, growth I; GII, growth II